Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share (the "Shares")
-
Shares outstanding
-
28,743,490
-
Total 13F shares
-
6,249,175
-
Share change
-
+1,105,184
-
Total reported value
-
$98,517,154
-
Price per share
-
$15.77
-
Number of holders
-
57
-
Value change
-
+$18,056,175
-
Number of buys
-
30
-
Number of sells
-
19
Institutional Holders of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (the "Shares") (ENTA) as of Q4 2025
As of 31 Dec 2025,
ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (the "Shares") (ENTA) was held by
57 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
6,249,175 shares.
The largest 10 holders included
VANGUARD GROUP INC, ACADIAN ASSET MANAGEMENT LLC, GEODE CAPITAL MANAGEMENT, LLC, RENAISSANCE TECHNOLOGIES LLC, Hillsdale Investment Management Inc., GOLDMAN SACHS GROUP INC, DIMENSIONAL FUND ADVISORS LP, JPMORGAN CHASE & CO, Connor, Clark & Lunn Investment Management Ltd., and BNP PARIBAS FINANCIAL MARKETS.
This page lists
57
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.